---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-087394"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:41:11.003620+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU

## Summary
- 14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.
- No serious adverse events or grade 3+ adverse events reported; well-tolerated with no hair/skin changes.
- Initial BEACON study data in CSU expected week of January 6, 2025, including 180mg Q8W cohort.
- Regulatory clearance obtained to enroll 180mg dose cohort (n=12) in SPOTLIGHT; full results H1 2025.
- Significant tryptase reduction observed (66% at 2 weeks) correlating with clinical responses.

## SEC filing metadata
- accession: 0001213900-24-087394
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390024087394/0001213900-24-087394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390024087394/ea0217519-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-087394
- JSON: https://secwatch.observer/filing/0001213900-24-087394.json
- Plain text: https://secwatch.observer/filing/0001213900-24-087394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.